Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renzhuchangle granule for diarrhoea-predominant irritable bowel syndrome
ISRCTN42639030Phase 2Completed
- Sponsor
- PuraPharm Corporation Limited
- Start
- Dec 2018
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing Renzhuchangle granule 8 g, Renzhuchangle granule 4 g + placebo 4 g and Placebo 8 g (3 arms). Primary endpoints: Abdominal pain score and Stool consistency. Started Dec 2018; status: completed.
02
Drugs
Renshu Changle
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ISRCTN42639030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN42639030.